Cells were imaged with widefield epifluorescence using a 20x PlanFluor (NA 0.45) phase contrast objective, using a SPECTRA X LED light source (Lumencor) for green fluorescence
If hair preservation is a primary concern and moderate weight loss is acceptable, discussing these alternatives with your prescriber is reasonable
Private insurers and employers in the U.S
(5) Ionescu M, Frohman LA
Braun Group embecta Download the FREE PDF Brochure: #Diabetes #DrugDelivery #MedicalDevices #Healthcare #Insulin #GLP1 #ConnectedHealth #DigitalHealth #MedicalTechnology #DiabetesCare #MarketResearch #HealthcareInnovation #LifeSciences #MediTechInsights To view or add a comment, sign in Global Diabetes Drug Delivery Devices Market Expected to Grow at 9% CAGR by 2031 The demand for advanced diabetes drug delivery devices is accelerating as the global burden of diabetes continues to rise

Cost Comparison Table Insurance Coverage Saxenda: FDA-approved for weight loss Some plans cover with prior authorization May have quantity limits or step therapy requirements Ozempic: FDA-approved for diabetes, not weight loss Often covered for diabetic patients Rarely covered for weight loss alone Wegovy: FDA-approved for weight loss Coverage varies widely Many plans exclude weight loss medications Cost Efficiency When comparing cost per outcome: Saxenda: At $200/month for 12 months ($2,400) producing 15-18 pounds loss = ~$133-160 per pound lost Semaglutide: At $199/month for 12 months ($2,388) producing 30-35 pounds loss = ~$68-80 per pound lost Semaglutide provides substantially better value when considering weight loss achieved per dollar spent